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Abstract 
  
 Organophosphorus compounds (OPs) are inhibitors of acetylcholinesterase. OPs are used 
in certain pesticides and are used in chemical warfare as nerve agents. Paraoxonase-1(PON1) is a 
serum hydrolase that naturally hydrolyzes OPs and could potentially be used as a therapeutic 
against OP poisoning. However, PON1 is not very soluble, stable, or active against OP 
substrates. PON1 has three cysteines, two of which form a disulfide in the folded form, which 
makes the protein more susceptible to misfolding with oxidation or disulfide scrambling. Many 
recombinant forms of PON1 (rePON1) have been made which enhance the solubility and 
expressibility of the enzyme (e.g. G3C9 and G2E6). In order to better understand the active site 
of the enzyme, a series of mutations near the active site were made in the G3C9 active site and 
tested for activity against paraoxon; phenylacetate; and a lab analog of G-nerve agents, CMP. 
Also, variants of the rePON1 have been engineered by Tawfik et al. that increase the catalytic 
efficiency of the enzyme (e.g. 4E9). In order to maintain the catalytic efficiency of 4E9 and 
simplify PON1 production, two different cysteine modified mutants were made to 4E9. These 
mutants were made by overlap PCR methods along with standard cloning techniques.  In order to 
maintain the catalytic efficiency of 4E9 but also make the enzyme more human-like, a gene was 
designed that has the 4E9 active site and only the surface polar mutations of G2E6. All three 
variants were expressed and purified by Ni-NTA affinity column chromatography. The activities 
of the variants are tested against various OP substrates such as paraoxon and a lab analog of G-
nerve agents, CMP. The results showed that the engineered variants proved to have similar 
activity to the parent, less drug-like molecules. 
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7 
Introduction: 
Organophosphorus Background 
 
 Organophosphorus compounds (OPs) are among the most toxic identified substances.1 
Across the developing world, acute OP pesticide poisoning causes tens of thousands of deaths 
each year.2 Originally, OPs were developed for use as pesticides or insecticides,3 but their 
extreme toxicity toward vertebrates has led to their use as chemical nerve agent weapons of mass 
destruction. OPs act as an indirect cholinergic agonist by irreversibly binding to the catalytic 
serine residue of acetylcholinesterase to prevent the breakdown of acetylcholine in the synaptic 
cleft.4  
 Acetylcholine is a neurotransmitter of the central and peripheral nervous system and 
functions as a neuromodulator. In the central nervous system, acetylcholine is released at the 
skeletal myoneural junctions.5 In the autonomic subdivision of the peripheral nervous system, 
acetylcholine is the principle neurotransmitter released by the terminal nerve endings of all 
postganglionic, parasympathetic nerves and in both sympathetic and parasympathetic ganglia. 
Acetylcholine binds to the nicotinic and muscarinic acetylcholine receptors.5 The 
overstimulation of these receptors, caused by the inhibition of acetylcholinesterase, can lead to 
muscarinic and nicotinic effects. Muscarinic effects include bradycardia, hypotension, 
rhinorrhea, bronchorrhea, bronchospasm, cough, increased salivation, nausea and vomiting, 
abdominal pain, diarrhea, fecal incontinence, urinary incontinence, blurred vision, increased 
lacrimation, miosis, and excessive sweating.5 Nicotinic effects include tachycardia, hypotension, 
weakness, cramps, and paralysis.5 
 As of now, OP poisoning is treated post-exposure with a cholinergic antagonist or 
oximes. Atropine is an example of a cholinergic antagonist that binds to the muscarinic 
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acetylcholine receptor to prevent the overstimulation by acetylcholine.5 Atropine does not 
prevent the binding of OPs to acetylcholinesterase and does not address the source of the 
poisoning. Oximes are strong nucleophilic agents that are known to reactivate the 
phosphorylated acetylcholinesterase by binding to the OP molecule. After exposure to select 
OPs, reactivation has been shown to be complete when oximes are administered one hour after 
exposure, but the effects are different with different OPs.5,6 In moderate and severe cases of OP 
poisoning, oximes appear to have no effect and do more harm than good.5,6 Both Atropine and 
oximes are post-exposure treatments to OP poisoning, but reaching the OP agent before it arrives 
at the synapse could be a more efficient therapeutic method. 
 The enzymatic inactivation of OPs has been suggested as a therapeutic strategy. The goal 
is to engineer a recombinant human protein to act as a therapeutic biological scavenger that 
would be able to reduce the OP concentration in affected blood.7 The target proteins known to 
have potential therapeutic properties against OPs are the human organophosphorous acid 
anhydride hydrolases (OPAHs), including human paraoxonase (huPON) and human 
butyrylcholinesterase.8 
 
Figure 1: Above are the molecular structures of two examples of nerve agents, VR and soman, and an example of 
an OP that is a metabolite of the pesticide parathione, paraoxon. A lab analog of G-agents, CMP, is also shown in 
the figure above. 
 
 
 
 
CMP 
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Therapeutic Agents 
 Human butyrylcholinesterase (HuBChE) has been produced as a scavenger. HuBChE 
parallels synaptic acetylcholinesterase9 in primary amino acid sequence, deduced secondary 
structure, and active site chemistry; the two enzymes also have overlapping specificity for 
substrates and inhibitors. One of the limitation of this bioscavenger is its stoichiometric (1:1 
ratio) nature of binding to nerve agents, requiring large amount of HuBChE (60 mg/kg in guinea 
pigs) for in vivo protection against 2 - 5 LD50 nerve agent exposure.10, 11, 12, 13, 14 Progress has 
been made in converting butyrylcholinesterase into a “catalytic scavenger” by changing the 
glycine at position 117 to a histidine in order to fuel the hydrolysis of the OP through an acid-
base mechanism.15 The affinity and catalytic activity of the mutant are lower than that of human 
paraoxonase-1 (huPON1).15 
 PON1 is one of three members of the PON family. PON1 and PON3 both associate with 
high density lipoprotein (HDL). Both proteins are capable of protecting low-density lipoproteins 
(LDL) against oxidative stress, reducing macrophage foam cell formation and preventing 
atherosclerosis development.16, 17 PON2 is expressed in nearly all tissues and does not associate 
with HDL particles in circulation. The PON family has been involved in the reduction of 
oxidative stress and the protection against atherosclerosis.16, 17 Furthermore, the ability of PON1 
to enzymatically hydrolyze OPs makes PON1 a protein of interest as a potential bioscavenger.  
 
Human Paraoxonase-1 
 HuPON1 is a serum-based, calcium-dependent enzyme that is mainly synthesized in the 
liver. PON1 exists in different polymorphic forms. The two common isoforms that have been 
extensively studied contain polymorphisms at position 55 and 192.14, 18, 19, 20 The former 
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influence the expression level of PON1 and the latter affects the enzymatic activity. PON1 
polymorphism in the promoter region is reported to influence the level of protein expression.20 
The physiological role of PON1 is still unclear, but evidence exists for its protective effect 
against oxidative modifications of lipoproteins.14, 17, 22, 23, 24 The crystal structure of huPON1 has 
not been solved; however, the crystal structure of a recombinant version, G2E6, which 
hydrolyzes esters including lactones and OPs has been solved.  
 
Figure 2: Model of the structure of huPON1 based on the X-ray crystal structure of a chimeric rabbit PON1 
variant. Important residues are rendered as sticks and colored for: Ca2+ binding (red and purple); putative sites of 
glycosylation (green); cysteines (orange); and putative site of HDL binding (yellow). Blue and purple residues have 
been found to affect the activity or specificity of PON1 in derivatization, mutational or evolutionary studies. The 
preponderance of the activity and structural evidence suggests that the active site lies in a pocket just above (and 
probably including) the Ca2+ binding site in the middle of the -barrel. The model was generated with SwissModel 
from PDB entry 1V04, and the figure was generated with PyMOL. 
*This figure and caption were taken from the proposal by Sayre, Magliery, & Wang. 
 There are some difficulties associated with using huPON1 therapeutically. First, it must 
be cheaply generated in large amounts without any contaminations of immunogens or pathogens 
from the vector organism. Second, PON1 has three cysteines, two that form a disulfide bond in 
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the folded form which makes the protein more susceptible to misfolding upon oxidation or 
disulfide scrambling. Third, its affinity for and turnover of nerve agents are weak.25,26 Fourth, 
huPON1 is not very stable and is not easily expressed.27 Efforts to improve huPON1 activity 
toward OPs are severely restricted by an incomplete understanding of the active site and 
mechanism. 
If recombinant PON1 (rePON1) variants are made that are very similar to huPON1 as 
well as soluble and expressible in E. coli, we will be able to better understand the location of its 
active site and the mechanisms it undergoes. Efforts have previously been made to enhance the 
expressibility of PON1. Tawfik and coworkers used DNA shuffling and activity screening to 
obtain the first PON1 variants that express in a soluble and active form in E. coli. One variant in 
particular, G3C9, yielded over 12 mg/liter culture of pure, active, unmodified PON1.16 
 
Figure 3: An SDS-PAGE gel showing two of the most expressible and soluble variants found, G3C9 and G3H8.16 
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Table 1: A comparison of the enzymatic activity of the variants made. All of the variants that are shown in the table 
maintained similar activity to the wild-type huPON1 against paraoxon and phenylacetate.16 
 
The rePON1, G3C9, variant has been used in structural and mechanistic studies because 
it, unlike huPON1, is soluble and expressible in E. coli.16 Bacterial expression enables 
compatibility to semi-rationally improve the properties of PON1. We can carry out mutagenic 
studies on the soluble rePON1, G3C9 variant; however, the protein sequence is not very similar 
to the human homolog. Therefore, it would be quite useful to engineer a soluble, E. coli 
expressible, PON1 variant that is a near-variant of the human homolog. Manufacturing huPON1 
variants for E. coli expression is necessary for improving its stability and ablating unfavorable 
properties. It would also be useful to involve a more efficient active site in the protein. 
 
Solubility and Active Site Modifications 
Fusion of a seemingly insoluble protein with more soluble bacterial proteins helps 
increase the solubility and expression levels of the test proteins.27, 28 Glutathione S-transferase 
(GST), thioredoxin (Trx) and Maltose Binding Protein (MBP) have been successfully applied as 
a fusion protein to increase the solubility and expressibility of a number of difficult-to-express 
proteins or human proteins.28, 29 (M311, 312) MBP has proven to be a better fusion partner to 
express protein with better solubility and higher yields.27, 28 
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Figure 4: A gel and chart summarizing the findings of Kapust et al. The SDS PAGE gel is of the generally insoluble 
protein, TIMP, fused with TRX, GST, or MBP. The gel shows that fusing an aggregation-prone protein to any 
highly soluble partner will routinely give rise to a soluble fusion protein. The chart illustrates that MBP is a much 
better solubilizing agent than GST or TRX MBP fusion.	   
 
A PON1 variant has been designed to increase the stability and solubility of huPON1. 
The variant incorporated changes in perceived surface residues of huPON1 that changed the 
residues to the more polar residue found at that position on the G2E6 rePON1. The variant was 
termed G2E6 polar (G2E6p). A total of 15 changes (I5T, N19R, Q21K, L31H, N78D, N80D, 
S81K, P82S, L96S, G101E, A137S, N166S, Q192K, Y197H, N265D and N309D) were made to 
the surface of PON1, which is less than the 59 residual variations between G2E6 and huPON1 or 
the 51 residual variations between G3C9 and huPON1.28  As a fusing to folding reporter green 
fluorescent protein (frGFP), Mohosin Sarkar was able to use fluorescent screening to show that 
G2E6p is more soluble than huPON1.28 frGFP distinguishes proteins that fold robustly and are 
highly soluble from those which aggregate. It has been observed that the solubility of a protein is 
directly correlated to the fluorescence of the cell.28 
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Figure 5: Fluorescent diagram showing huPON1 and G2E6p (labeled huPON1G) as well as some other variants. 
G2E6p or huPON1G is more fluorescent than huPON1. 
 
Recently, Dan Tawfik and coworkers used both applied and targeted mutagenesis to 
rePON1 and screened the mutants for organophosphate hydrolysis using both high-throughput 
fluorescence-activated cell sorting (FACS) screening and low-throughput plate screening. One of 
the variants reported, 4E9, had increased enzymatic efficiency against the more toxic, Sp, isomer 
of the nerve agent analog, CMP (shown in Figure 1). 29 4E9 varies from G3C9 in 6 positions 
(L69G, S111T, H115W, H134R, F222S, T332S), all of which are located in the putative active 
site of PON1.29 
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Table 2: This table summarizes the findings of Tawfik et al. from the fluorescence-activated cell sorting screening. 
Two interesting findings include 3B3 having most to all activity against the Rp, or less toxic isomer, and 4E9 has 
high activity against the Sp, or more toxic isomer.29 
 
In order to design a more humanlike variant with increased enzymatic efficiency, we 
designed a gene containing both sets of mutations in the huPON1 scaffold. This would increase 
the solubility of the human protein while hopefully maintaining the activity or enzymatic 
efficiency associated with 4E9. The resulting gene was termed 4E9 polar (4E9p). The gene 
includes 2 other residual mutations (A125T, V206T) that were not included when designing 
G2E6p. The gene exists both fused to MBP and without MBP. 
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Figure 6: The structure of rePON1 with the residual differences between huPON1 and 4E9p highlighted in red (if it 
is a surface mutation obtained from G2E6) and pink (if it is an active site mutation obtained from 4E9). 
 
 
 
              
Figure 7: Putative active site of rePON1 with the changed residues between G3C9 and 4E9 highlighted and labeled. 
 
T332S 
F222S 
H115W 
H134R 
L69G 
S111T 
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Cysteine Modifications 
PON1 has three cysteines (at positions 42, 283, and 353), two of which form a disulfide 
in the folded form (42-353). Cysteine residues can complicate the folding and storage of proteins 
due to improper formation of disulfide bonds or oxidation of reduced residues.30, 31 Oxidation can 
lead to changes in the physicochemical properties of a protein.30 These modifications range from 
changes in hydrophobicity and isoelectric point to conformational changes.30 Also, oxidation is a 
potential problem in protein production, isolation, and purification processes.30 Mutating 
cysteines to residues that are similar in size and shape such as alanine or valine can still yield a 
protein with similar folding and kinetic properties as the wild type. For example, Sanjay Hari and 
colleagues mutated the two cysteines (C38 and C52) of the protein Rop and concluded that the 
C38A C52V variant of Rop is active, has wild-type like thermal stability, exhibits a cooperative 
thermal denaturation, and has similar although slightly reduced stability to urea denaturation.30 
It would be preferable to have a therapeutic version of huPON1 that is Cys-free (or at 
least have only 1-2 Cys) without affecting the activity or folding of the enzyme. An experiment 
was executed using G2E6 as the scaffold in which a variety of cysteine (Cys) mutation 
combinations were changed to alanine (Ala) or valine (Val).32 The table below summarizes the 
activity findings using phenyl acetate as the substrate. 
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Table 3: This table shows the variations in kcat/Km in mM-1 min-1 among the different mutants using phenyl acetate 
as the substrate.32 
 
 The results concluded that the C42A and C353V (ACV) and C283V (CVC) mutants 
maintained similar activity to wild type. These two mutants were screened for activity under 
oxidizing conditions to yield the results shown in the figure below. 
 
Figure 8: A graph showing the % Residual Activity of CVC (blue), wild type (red), and ACV (green) against 
phenyl acetate versus various amounts of oxidizing agent (glutathione).32  
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The results showed that ACV and WT were susceptible to a loss in activity when under oxidizing 
conditions whereas CVC was not as susceptible to loss of function with increasing oxidizing 
agent.32 The findings encouraged the design of both the ACV and CVC mutants in the 4E9 
scaffold. 
 
 
Figure 9: The structure of rePON1 highlighting the three cysteine residues. In pink is C283 and in red is C42 and 
C353. These two are responsible for forming a disulfide bond. 
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Materials and Methods: 
Creation of Cys-free and G3C9 mutants 
  
Figure 10: Structure of rePON1 highlighting the residues mutated in G3C9. 
 
Variants Forward Mutagenic Primers Reverse Mutagenic Primers 
C42A AAC TCC AGT GGA ACT TCC TAA CGC TAA 
TTT AGT TAA AGG GGT TGA C 
GTC AAC CCC TTT AAC TAA ATT AGC GTT 
AGG AAG TTC CAC TGG AGT T 
L69G* GGC TTT CAT CAG CTC CGG AGG TAA GTA 
TCC TGG AAT AAT GAG 
CTC ATT ATT CCA GGA TAC TTA CCT CCG 
GAG CTG ATG AAA GCC 
L69S GGC TTT CAT CAG CTC CGG ATC AAA GTA 
TCC TGG AAT AAT GAG 
CTC ATT ATT CCA GGA TAC TTA GAT CCG 
GAG CTG ATG AAA GCC 
K70A* CTT TCA TCA GCT CCG GAT TAG CAT ACC 
CTG GAA TAA TGA GCT 
AGC TCA TTA TTC CAG GGT ATG CTA ATC 
CGG AGC TGA TGA AAG 
F222S GCA GAA GGA TTT GAC TCA GCT AAC 
GGA ATC AAC ATC TCA 
GAT GTT GAT TCC GTT AGC TGA GTC AAA 
TCC TTC TGC TCG 
L240S GTA TGT CTA TAT AGC TGA GTC GCT GGC 
TCA TAA GAT CCA TG 
CAT GGA TCT TAT GAG CCA GCG ACT CAG 
CTA TAT AGA CAT AC 
C283V AGG GGA TCT CTG GGT TGG TGT ACA TCC 
TAA CGG AAT GCG AAT C 
GAT TCG CAT TCC GTT AGG ATG TAC ACC 
AAC CCA GAG ATC CCC 
F292A CCC AAC GGA ATG CGA ATT GCC TAC TAT 
GAC CCA AAG AAT C 
GAT TCT TTG GGT CAT AGT AGG CAA TTC 
GCA TTC CGT TGG GAT G 
T332A* TGG CAC TGT GTT ACA GGG AAG AGC TGT 
GGC CGC TGT GTA CAA AG 
CTT TGT ACA CAG CGG CCA CAG CTC TTC 
CCT GTA ACA CAG TGC CA 
     L69 
     K70 
     F222 
     L240 
     F292 
     T332 
     V346 
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V346A AAA CTG CTG ATT GGC ACC GCG TTT CAC 
AAA GCT CTT TAC 
GTA AAG AGC TTT GTG AAA CGC GGT GCC 
AAT CAG CAG TTT C 
C353V CAG TGT TTC ACA AAG CAC TTT ACG TTG 
AGC TGG CGG CCG CAC TCG 
CGA GTG CGG CCG CCA GCT CAA CGT 
AAA GTG CTT TGT GAA ACA CTG 
 
Table 4: This table gives the nucleic acid sequences for all the mutagenic primers used for cloning the G3C9 
mutants as well as the Cys-free mutants in 4E9. Most of the mutants were cloned using Pfu polymerase. The mutants 
with * indicate that they were cloned using Herculase II polymerase. 
 
Variants Forward Cloning Primers Reverse Cloning Primers 
C42A, C353V, 
F292A, L69G, 
L69S, V346A 
GTG AGC GGA TAA CAA CAA TTC 
CCC CCA ACT CAG CTT CCT TTC GGG 
K70A, F222S, 
T332A, L240A GAT ATA CCC ATG GCT AAA CTG AAT AAT GCT CGA GTG CGG CCG C 
C283V (fragments) GAG GGG TAA TAA TTA GTG GTG 
GTG GTG GTG GTG 
TTA ACC GCA TTA ACT CTC TTG GGG 
CTG GGA TTG GCA C 
C283V (overlap) CTG CAC CAT CTC GAG GGG TAA 
TAA TTA GTG GTG GTG 
GGT GGT GGC CCA TGG CTA AAT TAA 
CCG CAT TAA CTC TCT TGG 
 
Table 5: This is a table of the cloning primers used to both complete the fragments for each mutant as well as to 
extend and amplify the overlap product.  
 
 Fragments were made doing a PCR reaction using the primers listed in the tables above. 
Once fragments were made, the fragments were joined/overlapped in a final PCR reaction to 
yield the final product. The final overlap product was then purified and digested using NcoI and 
XhoI. Below is a picture of a plasmid map of G3C9 with the cloning sites emphasized. 
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Figure 11: A plasmid map of G3C9 showing where the restriction enzymes used for cloning, NcoI and XhoI cut 
into the vector.  
 
Creation of 4E9polar with and without MBP 
 In order to make 4E9 polar in the lab, it would require making several mutations to the 
DNA encoding the huPON1 gene. In order to remove this obstacle, the gene was synthesized by 
Genewiz (New Jersey). The amino acid sequence wanted for the gene was reverse translated 
using a back translation tool, which provided selective codon usage models for several different 
organisms. Due to the use of E. coli for protein expression purposes, E. coli was the species of 
choice for the codon usage model. Also, the four least common codons in E. coli (CTA, CCC, 
CGA, and AGG) were not permitted to be included in the gene. For cloning purposes, an NcoI 
site was placed at the beginning of the gene and an XhoI site was placed at the end of the gene. 
Also, two BamHI sites were placed at the very beginning and very end of the gene (originally 
cloned into the pUC57 vector. Due to the insoluble nature of the human protein, the gene initially 
was to be placed as a fusion to MBP in the pET11 vector. In order to move the gene into the 
pET11-MBP construct, both the pUC57 construct (containing the gene) and a pET11-MBP 
construct were digested using BamHI. The resulting insert and vector were purified using 
dialysis membrane and glass fiber filter paper. Then a ligation of the vector and insert was 
carried out using T4 ligase. The ligation reaction was transformed into DH10B via electroporesis 
and plated on LB AMP plates. The resulting colonies were analytically digested with SalI and 
EcoRV.  
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Figure 12: The original plasmid map of the gene received from the order in the pUC57 vector. The BamHI, NcoI, 
and XhoI sites are emphasized to show all the usable cloning sites of the designed gene. 
 
 
Figure 13: A plasmid map of the MBP fused protein showing the NcoI and XhoI sites that were used to make the 
gene without a fusion to MBP. Also emphasized are the analytical restriction sites of SalI and EcoRV. 
 
In order to make the protein without the MBP fusion, the pET11-MBP-4E9 polar plasmid was 
cut with NcoI and XhoI and placed in the pET32 vector. 
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Figure 14: A plasmid map of 4E9 polar without MBP in the pET32 vector with the NcoI and XhoI cloning sites 
emphasized. 
 
Purification and Expression of Variants: 
 All protein expression was carried out using the Origami B (DE3) strain of cells. Every 
G3C9 and Cys-free variant was expressed and purified using the same protocol. For all of those 
variants, the cell were grown at 37 °C until it reached an OD600 ~0.8. The samples were then 
induced using 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and placed at 30 °C for ~4 
hours. The cells were then spun down to produce the pellet. The pellets were resuspended in ~45 
mL lysis buffer (50 mM Tris pH 8, 1 mM CaCl2, 50 mM NaCl, and 0.1 mM DTT). All of these 
variants were lysed on ice using a sonicator with the setting of 30 sec pulse, 2 minutes 30 sec 
pause, with a total pulse time of 3 minutes at a power of 6 W. For 4E9 polar, the cells were 
grown at 37 °C until it reached an OD600 of ~1 and induced using 0.3 mM IPTG at 16 °C 
overnight (~18 hours). The cells were centrifuged to obtain the pellet and the pellet was 
resuspended in ~45 mL lysis buffer. The 4E9 polar samples were lysed using an Emulsiflex to 
prevent over-heating of the protein. After lysing, 0.1% tergitol was added to all samples (Cys-
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free and G3C9 variants included). The samples were then placed on a nutator at 4 °C for 2.5 
hours. Equilibrated Ni-NTA resin (Qiagen) was added to the sample (0.3 mL per 1 L prep) and 
the samples were again placed on a nutator at 4 °C for ~3 hours to allow for the 6xHis tag located 
on the C-terminus of the protein to bind to the resin.  The samples were then poured into a 
column and the table below describes the wash and elution buffers used to obtain the purified 
sample. 
 
Activity buffer contains 50 mM Tris pH 8, 1 mM CaCl2, 50 mM NaCl, and 0.1% Tergitol 
Protocol is for a 1 L prep of protein 
Buffer Name Imidazole Concentration Volume Used 
Wash 1 10 mM ~45 mL 
Wash 2 10 mM ~45 mL 
Wash 3 25 mM ~25 mL 
Elution 1 150 mM ~12 mL 
Elution 2 150 mM ~15 mL 
 
Table 6: This table summarizes the washing and eluting steps involved in Ni-NTA affinity chromatography protein 
purification 
 
 All samples were examined by SDS-PAGE to ensure protein concentration and level of 
purity. Elution 1 was then buffer exchanged twice using a dialysis cassette. The first exchange 
took place in activity buffer plus 10% glycerol (anywhere between 2-4 L is fine). The second 
exchange occurred in activity buffer plus 50% glycerol (again, anywhere between 2-4 L is fine). 
The reason buffer exchange took place is to remove imidazole from the sample as well as protect 
the protein sample from freezing for storage through the addition of glycerol to the sample. The 
samples were removed from the cassettes and stored at -20 °C. 
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Enzyme Kinetics and Assays 
 Prior to collecting kinetic data, the concentration of enzyme must be known. To 
determine the concentration of protein in a sample, a Bradford assay was used. A Bradford assay 
uses the Bradford reagent that changes color upon binding to protein. The color that the dye 
changes is observed at a wavelength of 595 nm. In order for a Bradford to effectively predict the 
concentration of protein in a sample, a calibration curve must be made using known 
concentration of protein. The calibration curve was done on the SpectraMax Plus 384 
spectrophotometer using known concentration of Bovine Serum Albumin (BSA) ranging from 
0.05-0.5 mg/mL. Various dilutions of enzyme were made until a dilution was found which fits 
within the calibration curve. The values were triplicated and a concentration can be determined. 
To confirm if the concentration is correct, the samples were normalized to 1 mg/ml and 
electrophoresed on an SDS gel with samples of BSA. Once protein concentration is determined, 
the enzyme is ready for kinetic studies. 
Also, the concentration of substrate used must be known. The substrates paraoxon and 
phenyl acetate stock concentrations were confirmed through base hydrolysis. A strong base is 
added to a concentration of substrate that would give an absorbance value of 0.5. Depending on 
how off from 0.5, the absorbance values of the stock was adjusted to make up for the variation. 
To test the accuracy of the racemic CMP stock solution, the substrate is hydrolyzed using the 
rePON1, 3B3. 3B3 is known to hydrolyze only one of the two isomers. The final absorbance 
after hydrolysis is then used to calculate half the concentration of CMP in the stock. The stock 
concentration is then adjusted accordingly. 
Below is a description of the substrate parameters used to test the activity of all the 
variants. 
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Paraoxon: 
Final [Paraoxon] 
(mM) 
Initial [Paraoxon] 
(mM) 
Volume MeOH/mL 
(µL) 
Volume Previous 
Stock/mL (µL) 
2.6 130 973.0 27.0 
1.8 90 307.7 692.3 
1 50 444.4 555.6 
0.52 26 480.0 520.0 
0.26 13 500.0 500.0 
0.13 6.5 500.0 500.0 
0.06 3 538.5 461.5 
0.03 1.5 500.0 500.0 
 
Table 7: This table provides the concentrations of paraoxon used to collect the data points to fit the Michaelis-
Menten curve. It also provides the amounts used to make each solution. The final concentration of MeOH is 2%. 
 
Phenyl Acetate: 
Final [Phenyl 
Acetate] (mM) 
Initial [Phenyl 
Acetate] (mM) 
Volume of 
MeOH (µL) 
Volume of Previous 
Phenyl Acetate Stock 
(µL) 
3.3 165 979.1 20.9 
2.6 130 212.1 787.9 
1.8 90 307.7 692.3 
1.0 50 444.4 555.6 
0.52 26 480.0 520.0 
0.26 13 500.0 500.0 
0.13 6.5 500.0 500.0 
0.06 3 538.5 461.5 
 
Table 8: This table provides the concentrations of phenyl acetate used to collect the data points to fit the Michaelis-
Menten curve. It also provides the amounts used to make each solution. The final concentration of MeOH is 2%. 
 
 For paraoxon and phenyl acetate assays, 186 µL of assay buffer (50 mM Tris, 10 mM 
CaCl2 pH 7.4), 10 µL of enzyme, and 4 µL of substrate (200 µL total reaction) are added in that 
order to the well. To determine the concentration of enzyme to be used, serial dilutions are made 
in one column of a 96 well plate (ranging from neat enzyme to a 1:128 dilution). The absorbance 
at 412 nm and 270 nm for paraoxon and phenyl acetate respectively was observed for 3-5 
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minutes with readings every 10 seconds. A dilution was chosen based on the linearity of the rate 
of absorbance of the leaving group and the dilution was used to triplicate the series. Using Beer’s 
Law, the absorbance can be converted to concentration with a path length of 0.46 cm and the 
known extinction coefficients (ε) equal to17,000 M-1 cm-1 for paraoxon and 13,100 M-1 cm-1 for 
phenyl acetate. 
CMP: 
 To test for CMP activity, enzymes were incubated in assay buffer with increasing 
concentrations of either CMP from 0.005mM to 0.5mM in a 96-well plate. In terms of volume, 
146 µL of assay buffer, 50 µL of enzyme and 4 µL of substrate are added to the well. The rate of 
formation of the coumarin product was monitored at a wavelength of 405 nm (ε = 37,000 M-1 
cm-1) using SpectraMax Plus 384 spectrophotometer for 5-10 minutes. The stocks of CMP were 
prepared in MeOH, with a final concentration of 2% MeOH in the final reaction.  
 Another experiment was conducted to determine the activity of the enzyme against the 
more toxic, S isomer. As mentioned before, 3B3 turns over only one of the isomers, and it 
happens to be the less toxic isomer. To test for enzymatic activity against the more toxic isomer, 
3B3 is incubated in assay buffer and 0.033 mM CMP. This reaction sits for 10-15 minutes so all 
of the less toxic isomer will be hydrolyzed and only the more toxic isomer will remain. The 
enzyme to be tested is added to this reaction to make the final concentration of CMP in solution 
0.025 mM. Absorbance (at 405 nm) was observed over 10 second intervals for 5-10 minutes. A 
kcat/Km value can be extracted from the rate, substrate concentration and enzyme concentration. 
 
All kinetic parameters were collected by Michaelis-Menten steady-state kinetics (See 
Figure 15 for the equation). A Michaelis-Menten plot can be made by plotting the slope obtained 
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from the change in absorbance over time (converted to mM/min) versus the concentration of 
substrate used. 
    
Figure 15: The equation above is the Michaelis-Menten equation. Where Vmax is kcat [E]t. Experimentally, Km is the 
concentration of substrate at half Vmax. Vmax is the horizontal asymptote the curve is constricted to. 
 
The equation above can be manipulated depending on the concentration of substrate used. If the 
concentration of substrate is much smaller than the Km, it is possible to extract the enzymatic 
efficiency (kcat/Km) by simply dividing the rate by the substrate and enzyme concentration. 
However, if the substrate concentration is much larger than the Km value, it is possible to obtain 
the catalytic activity (kcat) of the enzyme by dividing the rate by the enzyme concentration. The 
kcat/Km is what is most commonly reported. Thus, the kcat/Km can be extracted by doing an assay 
at a single substrate concentration (a substrate concentration at least 10x less than the Km value). 
Cys-free Glutathione Oxidation Assays 
Concentration of 
GSSG (volume added 
from 100 mM stock) 
0 mM (0 µL) 5 mM (25 µL) 10 mM (50 µL) 20 mM (100 µL) 
Concentration of 
enzyme (volume added 
from 1 uM stock) 
0.1 uM (50 µL) 0.1 uM (50 µL) 0.1 uM (50 µL) 0.1 uM (50 µL) 
Volume of Assay 
Buffer Added 
450 µL 425 µL 400 µL 350 µL 
Total Reaction Volume 500 µL 500 µL 500 µL 500 µL 
Table 9: This table sums up the items added to each tube for the glutathione oxidation assays on the Cys-free 
variants. 
 
 Each reaction was placed in a 37 °C water bath for 40 minutes. After the 40 minutes of 
incubation, each sample was screened for activity against paraoxon. To obtain the activities of 
these variants, single point kinetics are done to yield a kcat/Km value. At 0 mM, GSSG is 
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considered to supply the 100% activity point. The other determined activities with GSSG present 
are compared to the 100% activity value to obtain the percent residual activity values upon 
oxidation. This can be plotted against concentration of GSSG to aid in visualizing variations 
amongst the mutants. 
 
Results and Discussion: 
Cloning, Expression, and Purification of Variants 
 All variants were successfully cloned and sequence confirmed. The variants were then 
expressed and purified. 
 
Figure 16: This is a multiple amino acid sequence alignment of huPON1, G2E6 polar, and 4E9 polar. It paints a 
picture of what residues were mutated from huPON1 to G2E6 polar to 4E9 polar. There are 16 mutations in G2E6p 
and 24 mutations in 4E9p when compared to huPON1 and only 8 mutations when compared to one another 
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Figure 17: SDS-PAGE purification pictures for huPON1-MBP, 4E9, 4E9 polar, 4E9 polar-MBP, ACV, and CVC. 
All gels were 1 L preps of the samples with 10 µl of elution loaded on to gel. 
Gel Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 Lane 6 Lane 7 Lane 8 Lane 9 Lane 10 
Gel 1 pellet lysate FT W1 W2 W3 M E1 E2 -- 
Gel 2 FT W1 W2 W3 M E1 E2 -- -- -- 
Gel 3 pellet FT W1 W2 W3 E1 M E2 -- -- 
Gel 4 pellet lysate FT M W1 W2 W3 E1 E2 -- 
Gel 5 M pellet lysate FT W1 W2 W3 E1 E2 E1 no DTT 
Gel 6 pellet lysate FT W1 W2 W3 M E1 E2 E1 no DTT 
FT-flow through, W1-wash 1, W2-wash 2, W3-wash 3, E1-elution 1, E2-elution 2, M-marker, DTT-reducing agent 
added to loading buffer. 
huPON1-MBP 4E9 
CVC ACV 
4E9p-MBP 4E9p 
 1      2      3       4      5      6      7      8      9    1        2        3         4        5       6        7      
  1      2       3       4       5       6       7       8     1      2       3       4      5      6      7      8      9 
 1      2      3     4      5    6      7      8      9    10  1      2      3     4      5     6     7     8     9     10 
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The gels above give a good indication of the yield achieved from the purification of each 
variant. HuPON1-MBP appears to have expressed well; however, there are several bands below 
the product. These bands are most likely degradation product due to the hydrophobicity and 
instability of the protein. 4E9 yielded the highest amount of protein per liter prep. 4E9p (without 
MBP) did not express well, but still gives pure product. 4E9p-MBP is more soluble, as is visible 
in the lysate lane. Although, 4E9p (without MBP) does not express well, it is still a promising 
prospect because it can be purified and yield up to 4 mg of product in a 1 L prep of protein. 
 In the ACV and CVC gels, the last lane does not contain the reducing agent, DTT, in the 
loading buffer. The formation of a dimer is visible on the ACV gel. The formation of a dimer, 
trimer, and tetramer are visible on the CVC gel. However, based on Image J densitometry 
calculations, more than 90% of ACV and CVC exist in the monomeric state. 
 
Enzyme Kinetic Data 
 The following table and charts summarize the kinetic data collected in the experiments as 
well as a Michaelis-Menten curve. 
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Figure 18: Michaelis-Menten plot of 4E9 when reacting with various concentrations of paraoxon (listed in Table 6). 
Error bars are also plotted and the data series is triplicated. M1 is equivalent to the Vmax and m2 is equivalent to the 
Km. 
 
G3C9	  Variants	  Kinetics	  Table	  
The	  kinetic	  data	  is	  listed	  in	  kcat/Km	  (mM-­‐1	  min-­‐1)	  with	  (Km	  in	  mM)	  
Variant Paraoxon Phenyl Acetate CMP 
G3C9* 61 (2.5) 7,200 (2.4) 60 (0.15) 
L69G* 15 (1.7) 62 150 (0.22) 
L69S* 4.9 31 -- 
K70A* 33 3,800 51 
F222S* 60 (0.6) 770 780 (0.04) 
L240S* 12 (0.27) 730 1,140 
F292A* 0.2 2,600 31.8 
T332A* 47 (1.5) 2,600 9 
V346A* 130 (1.3) 2,400 -- 
 
Table 10: This table gives the activities of all the G3C9 variants. All values are the kcat/Km in mM-1 min-1. In 
parenthesis next to the kcat/Km is the Km value in mM. A * indicates the data was collected by another lab member. 
For the G3C9 mutants, David Mata collected the phenyl acetate and paraoxon data and the results were collected at 
5% constant MeOH. Christina K. Harsch collected all of the CMP data.  
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G3C9 Mutant Results: 
 All of the mutants were reduced in phenyl acetate activity and most mutants lost 
paraoxon activity. Two mutants, F222S and L240S, had a ten-fold increase in CMP activity. The 
Km value of F222S, 0.04 mM, is much smaller than the Km of G3C9, 0.15 mM.  
 
Evolution	  of	  4E9p	  Kinetics	  Table	  
The	  kinetic	  data	  is	  listed	  in	  kcat/Km	  (mM-­‐1	  min-­‐1)	  with	  (Km	  in	  mM)	  
Variant Paraoxon Phenyl Acetate CMP 
huPON1* 46 (0.57) 88,000 (0.66) NSA 
G2E6p MBP* 4.1 1,310 NSA 
4E9p MBP 61 NSA 360 (0.04)* 
 
Table 11: This table gives the activities of 4E9p and the variants leading to the evolution of 4E9p, G2E6p and 
huPON1. All values are the kcat/Km in mM-1 min-1. In parenthesis next to the kcat/Km is the Km value in mM. A * 
indicates the data was collected by another lab member. The G2E6p and huPON1 data was collected by Dr. 
Mohosin Sarkar. Christina K. Harsch collected all of the CMP data. NSA- No significant activity. 
 
Cys-­‐free	  4E9	  Variants	  Kinetics	  Table	  
The	  kinetic	  data	  is	  listed	  in	  kcat/Km	  (mM-­‐1	  min-­‐1)	  with	  (Km	  in	  mM)	  
Variant Paraoxon Phenyl Acetate CMP 
4E9 1,700 (0.47) NSA 1,020 (0.02)* 
ACV 1,250 (0.43) NSA 880* 
CVC 726 (0.37) NSA 630* 
 
Table 12: This table gives the activities of Cys-free 4E9 variants. All values are the kcat/Km in mM-1 min-1. In 
parenthesis next to the kcat/Km is the Km value in mM. A * indicates the data was collected by another lab member. 
Christina K. Harsch collected all of the CMP data. NSA- No significant activity. 
 
4E9 Mutant Results: 
 4E9 had the highest activity against paraoxon and CMP amongst all of the mutants. ACV 
and CVC were both close to 4E9 in activity. Surprisingly, the mutant that disrupted the disulfide 
bond, ACV, maintained activity closer to wild-type than the mutant that disrupted the buried 
cysteine. This may be indicative of the buried cysteine playing a role in enzymatic 
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function/activity or folding/stability. Also, 4E9p is significantly more active than G3C9, 
huPON1, and G2E6p. All of the 4E9 mutants had no significant activity against phenyl acetate. 
Previous studies in lab found that the H115 position is necessary for wild-type-like phenyl 
acetate activity. The study mutated H115 to 10 different residues and all lost activity against 
phenyl acetate.33 
 
 
 
Figure 19: A bar graph comparing the activities of all the 4E9 variants (and parent molecules) that are active against 
paraoxon. 4E9 has the highest activity, followed by ACV, CVC, 4E9p, and G3C9. All of which have significantly 
higher activities than huPON1 and G2E6p. 
 
 
Figure 20: A bar graph comparing the activities of all the 4E9 variants (and parent molecules) that are active against 
CMP. 4E9 has the highest activity, followed by ACV, CVC, and 4E9p. All of which have significantly higher 
activities than G3C9. 
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Variants	  against	  Sp-­‐isomer	  
The	  kinetic	  data	  is	  listed	  in	  kcat/Km	  (mM-­‐1	  min-­‐1)	  
Variant Racemic Sp-isomer 
G3C9 16 0.1 
4E9 420 31 
4E9polar 110 31 
 
Table 13: This table displays the relative activities against racemic CMP and the Sp-isomer of CMP. All values are 
the kcat/Km in mM-1 min-1. Christina K. Harsch collected these data points. These are relative activities at 0.025 mM 
CMP concentration. 
 
Glutathione Oxidation Data 
 
Figure 21: A graph plotting the residual activity of the Cys-free mutants versus the concentration of GSSG. 
 Based on the results of the glutathione oxidation experiments, CVC was better able to 
maintain activity under oxidizing conditions. This makes sense considering CVC contains one 
less cysteine. ACV is currently being tested. Thus far, the results emulate the G2E6 glutothione 
oxidation results. 
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Summary and Future Directions: 
 
 G3C9 mutagenesis helped study the active site of PON1. It aided in underlining 
potentially important residues for structural stability and enzymatic activity. The 4E9 Cys-free 
variants maintained native-like activity and CVC was more stable and less prone to activity loss 
under oxidizing conditions than 4E9. 4E9polar has therapeutic potential against G-agents, 
considering its near human primary sequence. All of the 4E9 mutants will further be studied and 
characterized by testing activity against G agents as well as testing in animals to determine the 
extent of protection against OPs. Also, thermal inactivation and melts will be done on the 
variants to better characterize the stability of the protein. Error prone PCR can be used on 
4E9polar with aims to further enhance solubility while maintaining a human-like primary 
sequence. 
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